The Effects of Sodium Phosphate Supplementation on Physiological Responses to Submaximal Exercise and 20 km Cycling Time-Trial Performance by Brown, Jack A. & Glaister, Mark




The Effects of Sodium Phosphate Supplementation on Physiological Responses to Submaximal 1 
Exercise and 20 km Cycling Time-Trial Performance 2 
 3 
JACK ALEXANDER BROWN AND MARK GLAISTER. 4 
 5 
School of Sport, Health, and Applied Sciences, St Mary’s University, Strawberry Hill, Twickenham TW1 6 
4SX, UK. 7 
 8 
Contact information 9 
M. Glaister, School of Sport, Health, and Applied Sciences, St Mary’s University, Waldegrave Road, 10 
Strawberry Hill, Twickenham TW1 4SX, UK 11 
 12 
Tel: 0208 240 4012 13 
Fax: 0208 240 4212 14 
E-mail: mark.glaister@stmarys.ac.uk 15 
 16 













The aim of this study was to examine the effects of sodium phosphate (SP) supplementation on 26 
physiological responses to submaximal exercise and 20 km cycling time-trial performance. Using a 27 
randomised, double-blind, crossover design, 20 endurance-trained male cyclists (age: 31 ± 6 years; 28 
height: 1.82 ± 0.07 m; body mass: 76.3 ± 7.0 kg; maximal oxygen uptake [V̇O2max]: 57.9 ± 5.5 mL·kg-29 
1·min-1) completed two supplementation trials separated by a 14-day washout period. The trials 30 
consisted of 10 minutes of cycling at 65% V̇O2max followed by a 20 km time-trial. Expired air was 31 
monitored throughout each trial for the evaluation of V̇O2, minute ventilation (V̇E), and respiratory 32 
exchange ratio (RER). Heart rate was monitored during each trial along with ratings of perceived 33 
exertion (RPE) and blood lactate concentration. For four days before each trial, participants ingested 50 34 
mg∙kg fat-free-mass-1·day-1 of either SP or placebo. There were no effects (p ≥ 0.05) of supplementation 35 
on physiological responses during cycling at 65% V̇O2max. There were also no effects of 36 
supplementation on time-trial performance (placebo: 32.8 ± 2.2 mins; SP: 32.8 ± 2.3 mins). 37 
Nevertheless, relative to placebo, SP increased V̇E (mean difference: 3.81 L·min-1; 95% likely range: 38 
0.16-7.46 L·min-1), RER (mean difference: 0.020; 95% likely range: 0.004-0.036), and RPE (mean 39 
difference: 0.39; 95% likely range: 0.04-0.73) during time-trials; as well as post time-trial blood lactate 40 
concentration (mean difference: 1.06 mmol·L-1; 95% likely range: 0.31-1.80 mmol·L-1). In conclusion, 41 
SP supplementation has no significant effects on submaximal physiological responses or 20 km time-42 
trial performance. 43 
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INTRODUCTION 46 
Sodium phosphate (SP) is a legal nutritional supplement that has been suggested to improve 47 
athletic performance (Currell et al., 2012). Several mechanisms have been proposed to explain this 48 
potential ergogenic effect, including an increase in resting erythrocyte 2, 3-diphosphoglycerate (2, 3-49 
DPG) concentration (promoting oxygen offloading at the muscle via a reduction in oxyhaemoglobin 50 
affinity) (Bremner et al., 2002; Cade et al., 1984), an enhancement of myocardial contractility (Kreider 51 
et al., 1992), an increase in extracellular hydrogen phosphate (HPO4-) concentration (facilitating 52 
hydrogen ion buffering) (Buck et al., 2015; Kopec et al., 2016), and an increase in the activity of various 53 
oxidative enzymes, such as phosphofructokinase and glyceraldehyde 3-phosphate dehydrogenase 54 
(Buck et al., 2013).  55 
 56 
Given the above mechanisms, it has been hypothesised that SP supplementation may increase 57 
aerobic metabolism, and thus enhance endurance performance (Buck et al., 2013; Fukuda et al., 2010). 58 
In corroboration, despite one conflicting report (West et al., 2012), research into SP supplementation 59 
has consistently shown an increase in maximal oxygen uptake (V̇O2max) (Brewer et al., 2013; Cade et 60 
al., 1984; Czuba et al., 2009; Kreider et al., 1992; Kreider et al., 1990; Stewart et al., 1990). 61 
Nevertheless, research examining the effects of SP supplementation on endurance performance has 62 
produced conflicting results, with some studies reporting significant improvements (Folland et al., 63 
2008; Kreider et al., 1992), while others report no effect (Brewer et al., 2013, 2014; Buck et al., 2014; 64 
Kreider et al., 1990). It is also difficult to determine the effects of SP supplementation on physiological 65 
responses during endurance exercise, possibly because most investigations have evaluated those 66 
responses during self-paced time-trials or incremental tests rather than fixed-intensity bouts of exercise. 67 
As such, while some studies have shown a significant increase in oxygen uptake (V̇O2) following SP 68 
supplementation (Czuba et al., 2009; Kreider et al., 1990, 1992), others have observed no effect (Brewer 69 
et al., 2014; Folland et al., 2008). Similarly, some investigations have demonstrated a SP-induced 70 




decrease in heart rate (Czuba et al., 2009), whereas others have reported no effect (Brewer et al., 2013, 71 
2014; Folland et al., 2008; Kreider et al., 1990, 1992; West et al., 2012).   72 
 73 
It is difficult to attribute the conflicting responses of SP supplementation to methodological 74 
differences between studies, since discrepant findings exist regardless of differences in dosing 75 
strategies, mode of exercise, or participant training status. Indeed, despite some differences in the 76 
duration of supplementation (typically 6 days) the dose range used in previous research is very small 77 
(3.3-4.0 g·day-1; Buck et al., 2013). Moreover, all studies into SP supplementation have used trained 78 
participants; though between-study differences in V̇O2max (50-75 mL·kg-1·min-1) support clear 79 
differences in levels of ability. The issue of training status is important since well-trained athletes have 80 
been shown to have already elevated resting erythrocyte 2, 3-DPG levels (Brodthagen et al., 1985), 81 
likely due to an adaptive training response (Mairbäurl, 2013). However, the suggestion that well-trained 82 
athletes may be less responsive to the potential ergogenic benefits of SP supplementation seems unlikely 83 
considering that previous research has demonstrated that SP can improve time-trial performance in 84 
those individuals (Folland et al., 2008; Kreider et al., 1992). 85 
 86 
The factor that explains most likely the discrepant findings regarding the effects of SP 87 
supplementation on endurance performance is statistical error associated with the use of small sample 88 
sizes (Button et al., 2013). Small sample sizes reduce the chances of finding a true effect as well as 89 
reducing the likelihood that a statistically significant finding reflects a real effect (Button et al., 2013). 90 
Indeed, of those studies that have investigated the effects of SP supplementation on endurance 91 
performance, the largest sample size was 13 (Buck et al., 2014), with most using sample sizes ≤ 10 92 
(Brewer et al., 2013, 2014; Folland et al., 2008; Kreider et al., 1990, 1992). The principal aim of this 93 
study was therefore to address the issue of sample size in order to examine the effects of SP 94 
supplementation on endurance (20 km cycling time-trial) performance. In addition, by examining the 95 
effects of SP supplementation on physiological responses during both fixed-intensity submaximal 96 




cycling and time-trial performance, the study also aimed to provide insight into the potential 97 




Twenty endurance-trained (De Pauw et al., 2013) male cyclists and triathletes volunteered for 102 
the study, which was approved by St. Mary’s University Ethics Committee. Sample size calculations 103 
were performed based on the results of previous investigations into the effects of SP supplementation 104 
on endurance performance (Brewer et al., 2013, 2014; Buck et al., 2014; Folland et al., 2008; Kreider 105 
et al., 1990, 1992). Using the associated effect sizes, a power of 0.8, and a p value of 0.05, the analyses 106 
produced sample sizes ranging from 2 to 20,000. Given the practical limitations associated with 107 
recruiting trained participants, a sample size of 20 was chosen as it fell within the range determined 108 
from the calculations and was, with one exception (n = 13), at least double the sample size used in 109 
previous investigations. Before testing, participants received written and verbal instructions regarding 110 
the nature of the investigation and completed a training history questionnaire, which indicated that all 111 
had been actively involved in road cycling for at least one year. Time spent training each week was 112 
reported as 9.4 ± 3.9 hours. Before commencement of the study, all participants completed a health-113 
screening questionnaire and provided written informed consent. Means ± standard deviation for age, 114 
height, body mass, fat-free-mass (FFM), and V̇O2max of the participants were: 31 ± 6 years, 1.82 ± 0.07 115 
m, 76.3 ± 7.0 kg, 67.3 ± 6.3 kg, and 57.9 ± 5.5 mL·kg-1·min-1, respectively. Participants were instructed 116 
to maintain a consistent training volume throughout the study and to follow the same diet for 24 hours 117 
before all trials. Participants were also instructed to avoid food and drink for 1 hour before all trials and 118 
to abstain from caffeine, alcohol, and strenuous exercise for 24 hours before all trials. 119 
 120 
Experimental overview  121 




Participants were required to complete one preliminary trial followed by two experimental 122 
trials. The preliminary trial was used to provide descriptive data and to determine the fixed-intensity 123 
submaximal cycling workloads employed during the first part of the experimental trials. The 124 
experimental trials were performed in a crossover, randomised, counterbalanced, and double-blinded 125 
manner, separated by 14 days to allow for the washout period of SP (Cade et al., 1984). In line with 126 
strategies used in previous research (Buck et al., 2013), for four consecutive days before each 127 
experimental trial, participants ingested 50 mg∙kg FFM-1∙day-1 of either tribasic SP dodecahydrate (Iron 128 
Power, Melbourne, Australia) or placebo (maltodextrin; My Protein, Manchester, United Kingdom). 129 
Daily amounts were divided into four equal doses, with each dose administered in an opaque gelatine 130 
capsule (My Protein, Manchester, United Kingdom). As in previous research (Brewer et al., 2013, 2014; 131 
Buck et al., 2014), doses were ingested at ~4 hour intervals with a meal and ~300 mL of water to prevent 132 
gastrointestinal discomfort. Exercise, other than the time trials, was performed on an 133 
electromagnetically-braked cycle ergometer (Lode Excalibur Sport, Lode BV, Groningen, The 134 
Netherlands). Time trials were performed on a racing bicycle (San Remo, Claud Butler, Brigg, United 135 
Kingdom) seated on a motor-braked turbo trainer (Tacx Genius, Aardenburg, the Netherlands). 136 
Ergometers of this type have previously been shown to have very good test-retest reliability for 20 km 137 
time-trial performance (Peiffer & Losco, 2011). The cycle ergometer and the racing bicycle were fitted 138 
with clipless pedals and the participants cycled using their own cycling shoes. Saddle height and 139 
handlebar position for each participant were determined during the preliminary trial to enable 140 
replication in subsequent trials. Prior to all trials equipment was calibrated in accordance with 141 
manufacturer instructions. 142 
 143 
Procedures 144 
Preliminary trial 145 
All trials were performed at the same time of day (± 2 hours) in an air-conditioned laboratory 146 
maintained at a temperature of 18°C. The preliminary trial began with the calculation of participant 147 




FFM using air-displacement plethysmography (device for measuring volume changes within a body) 148 
(BOD-POD, Life Measurement Inc., Concord, CA, USA). Subsequently, participants performed an 149 
incremental exercise test which began at 120 W and increased by 20 W every 3 minutes. Participants 150 
were given 30 s during the first stage to achieve a comfortable cadence and were instructed to maintain 151 
this throughout the remainder of the incremental tests. Each stage was followed by 30 s of passive rest, 152 
during which 20 μL of capillary blood was obtained from the earlobe and analysed for blood lactate 153 
concentration using an automated analyser (Biosen C-Line, EKF Diagnostic, Barleben, Germany). The 154 
test was terminated when a blood lactate concentration ≥ 4 mmol∙L-1 was attained. After 5 minutes of 155 
passive rest, the maximal phase of the incremental exercise test began at 160 W and increased by 20 W 156 
every minute. The test was terminated when participants reached volitional exhaustion, at which time a 157 
final blood lactate concentration measurement was obtained. Throughout both phases of the incremental 158 
exercise test, participants breathed room air through a facemask (Hans Rudolph, Kansas City, MO, 159 
USA) that was secured in place by a head-cap assembly (Hans Rudolph, Kansas City, MO, USA). 160 
Expired air was monitored continuously using an online gas analyser (Oxycon Pro, Jaeger, Hoechberg, 161 
Germany). The analyser was calibrated before each trial using oxygen and carbon dioxide gases of 162 
known concentrations (Cryoservice, Worcester, UK), and the flowmeter was calibrated using a 3 L 163 
syringe (Viasys Healthcare GmbH, Hoechberg, Germany). All V̇O2 data were filtered to eliminate 164 
values that were outside four standard deviations of the local mean (the two breaths preceding and 165 
following the breath of interest). Oxygen demand for each of the submaximal incremental stages was 166 
determined as the average V̇O2 during the final 30 s of each 3-minute stage. V̇O2max was determined as 167 
the highest 30 s average V̇O2 recorded during the maximal phase of the test provided that at least two 168 
of the following criteria had been met: (a) a plateau in V̇O2, as determined by an increase of less than 2 169 
mL·kg-1·min-1 over the previous stage, (b) a heart rate within 10 b·min-1 of age-predicted maximum, (c) 170 
a respiratory exchange ratio (RER) ≥ 1.15, and (d) a blood lactate concentration ≥ 8 mmol·L-1. Linear 171 
regression and individual power output-V̇O2 relationships were used to calculate the fixed-intensity 172 
submaximal cycling workloads required to elicit 65% of V̇O2max, to be employed during the 173 
experimental trials. After a 10-minute recovery period, where participants cycled at a self-selected low 174 




intensity, a familiarisation 20 km time-trial (same protocol as in the experimental trials) was performed 175 
to minimise any potential changes in performance due to learning. 176 
 177 
Experimental trials 178 
Prior to each experimental trial, participants rested in a seated position for 5 minutes, after 179 
which 300 μL of capillary blood was collected from the earlobe. Blood samples were left to clot at room 180 
temperature for 60 minutes before being centrifuged at 4000 rpm for 10 minutes at 4°C. Subsequently 181 
decanted serum samples were frozen at -80°C until analysed for serum phosphate concentration using 182 
an automated analyser (Monza, Randox, London, UK). Participants then performed 10 minutes of 183 
cycling at 65% of the power output required to elicit V̇O2max, maintaining the same cadence as in the 184 
submaximal incremental test during the preliminary trial. Oxygen uptake, minute ventilation (V̇E), RER, 185 
and heart rate (RCX3, Polar Electro Oy, Kempele, Finland) were monitored continuously during cycling 186 
at 65% V̇O2max and averaged over the final 30 s of each 5-minute split to provide mean responses at 5 187 
minutes and 10 minutes. Blood lactate concentration and rating of perceived exertion (RPE; 15-point 188 
scale; Borg, 1970) were also determined at 5 minutes and 10 minutes during cycling at 65% V̇O2max. 189 
After 10 minutes of passive rest, participants completed a 20 km time-trial on the turbo trainer with the 190 
bicycle rear tyre pressure at 100 psi. The time-trial was performed against a resistance designed to 191 
replicate outdoor, level-gradient cycling conditions. No verbal encouragement was provided and all 192 
measures of elapsed time were removed from the environment. The only pertinent information visible 193 
to participants throughout each time-trial was the distance completed. Participants were free to change 194 
cadence and gears throughout each time-trial; however, the gearing chosen during the familiarisation 195 
time-trial was noted and used to standardise the starting intensity for the experimental time-trials. 196 
Distance completed, power output, and cadence were recorded at 1 Hz throughout each experimental 197 
time-trial. Expired air was monitored continuously throughout each experimental time-trial for the 198 
evaluation of V̇O2, V̇E, and RER. Heart rate was monitored continuously throughout each experimental 199 




time-trial and RPE was recorded at 5 km intervals. Blood lactate concentration was determined 1 minute 200 
before and immediately after each experimental time-trial. 201 
 202 
Statistical analyses 203 
All data were analysed using the Statistical Package for the Social Sciences (version 22, IBM 204 
SPSS, Armonk, NY, USA). Data are presented as means ± standard deviation, and 95% confidence 205 
intervals are provided for all estimates. A paired samples t-test was used to determine the effects of 206 
supplementation on resting serum phosphate concentration. Two-way (supplement × time) analyses of 207 
variance (ANOVAs) were used to determine the effects of supplementation and time on physiological 208 
responses (V̇O2, V̇E, RER, heart rate, RPE, and blood lactate concentration) during exercise at 65% 209 
V̇O2max. Two-way (supplement × 5 km split) ANOVAs were used to determine the effects of 210 
supplementation and 5 km splits on 20 km time-trial performance measures (completion time, power 211 
output, and cadence) and physiological responses (V̇O2, V̇E, RER, heart rate, and RPE). A two-way 212 
(supplement × time) ANOVA was used to determine the effects of supplementation and time on blood 213 
lactate concentration prior to and immediately following time-trial performance. Violations to 214 
assumptions of sphericity were adjusted using the Greenhouse-Geisser correction factor (Field, 2013). 215 
Significant effects were followed up using post hoc tests with Bonferroni adjustments (Field, 2013). 216 
The significance level was set at p < 0.05 for all analyses.  217 
 218 
RESULTS  219 
Serum phosphate  220 
Placebo supplementation resulted in a resting serum phosphate concentration of 0.77 ± 0.18 221 
mmol·L-1, whereas SP supplementation resulted in a resting serum phosphate concentration of 0.76 ± 222 
0.15 mmol·L-1. There was no significant effect of supplementation on resting serum phosphate 223 
concentration (p = 0.762). 224 





Physiological responses to submaximal fixed-intensity exercise 226 
The mean power output during the submaximal exercise bouts was 186 ± 34 W. There was no 227 
significant effect of supplementation on V̇O2 (p = 0.694), V̇E (p = 0.950), RER (p = 0.298), heart rate (p 228 
= 0.885), RPE (p = 0.650), or blood lactate (p = 0.375) during cycling at 65% of V̇O2max (Table 1). 229 
There was also no significant effect of time on V̇O2 (p = 0.766) or RER (p = 0.656). However, there 230 
was a significant effect of time on V̇E (p = 0.001), heart rate (p < 0.001), RPE (p < 0.001), and blood 231 
lactate (p = 0.033). Post hoc tests revealed that from 5 min to 10 min, V̇E, heart rate, and RPE increased 232 
significantly, whereas blood lactate decreased significantly. There were no significant supplement × 233 
time interactions for V̇O2 (p = 0.982), V̇E (p = 0.777), RER (p = 0.495), heart rate (p = 0.641), RPE (p 234 
= 0.095), or blood lactate (p = 0.573).  235 
 236 
Time-trial performance  237 
There was no significant effect of supplementation on completion time (p = 0.975), power 238 
output (p = 0.777), or cadence (p = 0.503) during the time-trials (Table 2). However, there was an effect 239 
of 5 km split on completion time (p < 0.001), with significant differences between all comparisons apart 240 
from that between the 5-10 and 10-15 km splits. Similarly, there was a significant effect of 5 km split 241 
on power output (p < 0.001). Post hoc tests revealed that participants produced a significantly higher 242 
power output in the final 5 km of each time-trial in comparison with each of the other 5 km splits. There 243 
was also an effect of 5 km split on cadence (p = 0.001), with significantly increased values in the 5-10 244 
and 15-20 km splits, when compared with the 0-5 km split. There were no significant supplement × 5 245 
km split interactions for completion time (p = 0.505), power output (p = 0.512), or cadence (p = 0.566). 246 
 247 
Time-trial physiological responses 248 




Participants completed the placebo and SP experimental time-trials at a mean intensity of 83 ± 249 
8% of V̇O2max. There was no significant effect of supplementation on V̇O2 (p = 0.944) or heart rate (p = 250 
0.141) during the time-trials (Table 3). However, there was an effect of 5 km split on V̇O2 (p = 0.012), 251 
with significantly increased values in the 15-20 km split, when compared with the 0-5 and 10-15 km 252 
splits. There was also an effect of 5 km split on heart rate (p < 0.001), with mean values increasing 253 
throughout the time-trials and with post hoc tests revealing significant differences between all 254 
comparisons apart from that between the 5-10 and 10-15 km splits. There were no significant 255 
supplement × 5 km split interactions for V̇O2 (p = 0.701) or heart rate (p = 0.111). 256 
 257 
There was an effect of supplementation on V̇E (p = 0.042) during the time-trials (Table 3), with 258 
SP resulting in significantly higher values than placebo (mean difference: 3.81 L·min-1; 95% likely 259 
range: 0.16-7.46 L·min-1). There was also an effect of 5 km split on V̇E (p < 0.001), with mean values 260 
increasing throughout the time-trials and with post hoc tests revealing significant differences between 261 
all comparisons apart from that between the 5-10 and 10-15 km splits. However, there was no significant 262 
supplement × 5 km split interaction for V̇E (p = 0.103). There was also an effect of supplementation on 263 
RER (p = 0.020) during the time-trials (Table 3), with SP resulting in significantly higher values than 264 
placebo (mean difference: 0.020; 95% likely range: 0.004-0.036). However, there was no significant 265 
effect of 5 km split on RER (p = 0.095) and no supplement × 5 km split interaction (p = 0.978). 266 
 267 
There was an effect of supplementation on RPE (p = 0.030) during the time-trials (Table 3), 268 
with SP resulting in significantly higher values than placebo (mean difference: 0.39; 95% likely range: 269 
0.04-0.73). There was also a significant effect of 5 km split on RPE (p < 0.001). Post hoc tests revealed 270 
a progressive increase in RPE throughout the time-trials with significant differences between all 271 
comparisons. However, there was no significant supplement × 5 km split interaction for RPE (p = 272 
0.632).  273 
 274 




There was a significant effect of supplementation on blood lactate concentration (p = 0.003; 275 
Figure 1). Blood lactate concentration also significantly increased from pre-time-trial to post-time-trial 276 
(p < 0.001). Moreover, there was a significant supplement × time interaction (p = 0.006). Post hoc tests 277 
revealed that there was no significant effect of supplementation on pre-time-trial blood lactate 278 
concentration (p = 0.738); however, relative to placebo, post-time-trial blood lactate concentration was 279 
significantly increased with SP (mean difference: 1.06 mmol·L-1; 95% likely range: 0.31-1.80 mmol·L-280 
1; p = 0.004).  281 
 282 
DISCUSSION 283 
The principal aim of this study was to examine the effects of SP supplementation on 20 km 284 
cycling time-trial performance. The key finding was that SP supplementation had no significant effect 285 
on time-trial completion time. Supplementation with SP also had no significant effect on power output 286 
or cadence during the time-trials. The absence of any significant effect of SP supplementation on time-287 
trial performance is consistent with some reports (Brewer et al., 2013, 2014; Buck et al., 2014; Kreider 288 
et al., 1990), but not others (Brewer et al., 2015; Folland et al., 2008; Kreider et al., 1992). However, it 289 
is worth noting that the small sample sizes associated with previous research increase the risk of false 290 
positives and reduce the likelihood that findings reflect a true effect (Button et al., 2013). Given that 291 
the present study was the first to examine the effects of SP supplementation on time-trial performance 292 
using a relatively large sample size, the findings of the present investigation add considerable weight to 293 
the argument that SP supplementation provides no ergogenic benefit during time-trial performance. 294 
 295 
Resting serum phosphate concentrations in the present study were slightly lower than 296 
anticipated, but were within the normal range for adults (Buck et al., 2013). Nevertheless, relative to 297 
placebo, the present study demonstrated no SP-induced increase in resting serum phosphate 298 
concentration. Apart from one exception (Czuba et al., 2009), previous research has also reported no 299 
change in serum phosphate concentration following SP supplementation (Brewer et al., 2013; Buck et 300 




al., 2015; Kopec et al., 2016; Kreider et al., 1990; Stewart et al., 1990). Given similarities in the dosing 301 
strategies used in these investigations, it seems, as highlighted by others (Buck et al., 2015; Kopec et 302 
al., 2016; Kreider et al., 1992; Stewart et al., 1990), that the measure may not be the best indicator of 303 
SP loading effects.  304 
A secondary aim of the present study was to investigate the potential mechanisms behind the 305 
ergogenic effects of SP supplementation. If, as hypothesised, SP supplementation improves oxygen 306 
offloading at the muscle via an increase in erythrocyte 2, 3-DPG levels (Bremner et al., 2002; Cade et 307 
al., 1984), then an enhancement of aerobic metabolism would be expected. However, given that there 308 
was not only no SP-induced improvement in time-trial performance, but also no increase in V̇O2 during 309 
either fixed-intensity submaximal cycling or time-trial performance, the findings of the present study 310 
fail to provide support for the above mechanism. Given that the period of fixed-intensity submaximal 311 
cycling was performed at a lower intensity than the time-trials, it seems unlikely that the absence of an 312 
effect of SP on V̇O2 could be due to exercise intensity. Although resting erythrocyte 2, 3-DPG levels 313 
were not measured in the present study, an alternative explanation for the lack of any increase in V̇O2 314 
is that SP supplementation may not increase 2, 3-DPG concentration in red blood cells. Indeed, of those 315 
studies that have measured 2, 3-DPG concentrations following SP supplementation, Cade et al. (1984) 316 
and Stewart et al. (1990) reported significant increases, Buck et al. (2015), Czuba et al. (2008), Kopec 317 
et al. (2016), and Kreider et al. (1992) reported no change, and Kreider et al. (1990) reported a 318 
significant decrease. Once again, the use of a small sample sizes may have influenced these findings 319 
along with the fact that erythrocyte 2, 3-DPG levels are already elevated in endurance trained 320 
individuals (Brodthagen et al., 1985; Buck et al., 2013) and can change rapidly post-sampling (Llohn 321 
et al., 2005).  322 
 323 
An alternative mechanism by which SP supplementation has been suggested to increase aerobic 324 
metabolism is via an enhancement of myocardial contractility (Buck et al., 2013; Fukuda et al., 2010). 325 
Indeed, using cardiac ultrasound and colour flow Doppler technology, Kreider et al. (1992) reported 326 




SP-induced increases in various measures of cardiac function in well-trained athletes, albeit 327 
concomitant with increases in time-trial performance (Kreider et al., 1992). Then again, there were few 328 
effects of SP supplementation on those same measures when compared at each intensity during an 329 
incremental test, or when compared at the same relative intensity (anaerobic threshold). Moreover, 330 
although heart rate values alone are unlikely to be a reliable indicator of cardiac function; it is worth 331 
highlighting that the present study, and several others have reported no SP-induced change in heart rate 332 
during time-trial performance (Brewer et al., 2013, 2015; Folland et al., 2008; Kreider et al., 1990). 333 
Overall, considering that the present study found no effect of SP supplementation on V̇O2 or time-trial 334 
performance, it appears that any effect of SP on cardiac function does not translate into any ergogenic 335 
benefit.  336 
 337 
It is difficult to explain how SP increased RER during the time-trial in the present study, but 338 
had no effect on RER during fixed-intensity submaximal cycling. Although the latter is supported by 339 
research showing no effect of SP supplementation on RER during submaximal incremental exercise 340 
(Kreider et al., 1992); previous research investigating the effects of SP supplementation on RER during 341 
time-trial performance has contrastingly reported no effect, despite a SP-induced increase in power 342 
output (Folland et al., 2008; Kreider et al., 1992). In the present study, a SP-induced increase in RER, 343 
in the absence of any change in V̇O2 during the time-trial, would support the corresponding increase in 344 
V̇E, as a result of an associated increase in V̇CO2. Then again, it is difficult to reconcile that response in 345 
the absence of any change in performance. To add to the confusion; of those studies that observed no 346 
SP-induced change in RER despite an increase in time-trial performance, Folland et al. (2008) reported 347 
no corresponding change in V̇E, while Kreider et al. (1992) reported an increase. Moreover, Brewer et 348 
al. (2014) reported no change in performance and no change in V̇E.  349 
 350 
As with the above, it is difficult to reconcile how, in the absence of any change in performance, 351 
blood lactate concentrations in the present study increased following SP supplementation in the time 352 




trial, but not during fixed-intensity submaximal exercise. Previous research has shown that SP 353 
supplementation has no significant effect on post-time-trial blood lactate concentration regardless of 354 
whether there was an increase in performance (Folland et al., 2008; Kreider et al., 1992 ) or not (Brewer 355 
et al., 2013, 2014; Buck et al., 2014). In the present study, the increase in post-time-trial blood lactate 356 
concentration is consistent with the corresponding increase in RER and V̇E resulting from the need to 357 
buffer associated hydrogen ions. However, an increase in blood lactate concentration generally indicates 358 
an enhancement of anaerobic energy provision (Maughan & Gleeson, 2004) which, in the absence of 359 
any change in V̇O2, would normally suggest an increase in performance. Similar contradictions in the 360 
present study exist concerning RPE, with significant SP-induced increases during the time-trial, despite 361 
no change in performance, contrasting with no effect of SP during fixed-intensity submaximal cycling. 362 
Moreover, the result is in contrast with previous studies showing that SP has no effect on RPE during 363 
(Folland et al., 2008; Kreider et al., 1990) or immediately after time-trial performance (Brewer et al., 364 
2014); though differential effects on performance add to the confusion. Given that the RPE scale was 365 
initially validated against heart rate (Borg, 1970), it was unsurprising that the absence of an effect of 366 
SP supplementation on heart rate during fixed-intensity submaximal cycling coincided with no SP-367 
induced change in RPE. However, it is unclear as to why the same response was not reflected during 368 
the time-trials. One potential explanation for the increase in RPE during the time trials is that it was 369 
induced by the corresponding increase in V̇E. In partial support, it has recently been shown that 370 
breathing frequency correlates very strongly (r = 0.89) with RPE during time-trial performance (Nicolò 371 
et al., 2016).  372 
 373 
In conclusion, the results of the present study indicate that SP supplementation has no 374 
significant effect on time-trial performance. Indeed, the associated increase in RPE suggests that SP 375 
supplementation may result in endurance athletes having to work subjectively harder to achieve the 376 
same level of time-trial performance. Given that SP has been proposed to improve endurance 377 
performance primarily via aerobic mechanisms, the absence of any SP-induced change in V̇O2 or heart 378 
rate provides further support for this lack of an ergogenic benefit. Notably, SP supplementation 379 




increased RER and V̇E during the time-trials and resulted in a higher post-time-trial blood lactate 380 
concentration all of which are difficult to explain; particularly given the absence of a corresponding 381 
effect during submaximal exercise or any effect on time trial performance.  382 
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Table 1. The effects of sodium phosphate supplementation on various physiological responses during 461 
10 minutes of cycling at 65% of the power output required to elicit maximum oxygen uptake (N = 20). 462 














 5 3.02 ± 0.47 69.76 ± 12.25 0.88 ± 0.06 128.1 ± 9.0 11.5 ± 1.4 1.76 ± 0.99 
 10 3.02 ± 0.40 72.01 ± 11.35 0.88 ± 0.05 130.9 ± 10.2 12.2 ± 1.1 1.55 ± 1.16 
 5 3.01 ± 0.47 69.99 ± 11.19 0.89 ± 0.06 128.2 ± 11.5 11.1 ± 1.4 1.83 ± 1.01 
 10 3.00 ± 0.52 71.93 ± 11.56 0.89 ± 0.04 131.3 ± 12.5 12.3 ± 1.6 1.65 ± 1.33 
Note: SP = sodium phosphate; V̇O2 = oxygen uptake; V̇E = minute ventilation; RER = respiratory exchange ratio; 464 
RPE = rating of perceived exertion; BLC = blood lactate concentration. 465 
Table 2. The effects of sodium phosphate supplementation on completion time, power output, and 466 
cadence during a 20 km cycling time-trial (N = 20). Values are means ± standard deviation.  467 
Supplement Distance (km) Completion time (min) Power output (W) Cadence (rpm) 
 0-5 8.40 ± 0.58 285 ± 56 96 ± 9 
 5-10 8.18 ± 0.56 293 ± 55 97 ± 8 
Placebo 10-15 8.21 ± 0.58 290 ± 57 97 ± 8 
 15-20 7.97 ± 0.55 317 ± 58 98 ± 9 
 0-20 32.76 ± 2.20 296 ± 54 97 ± 8 
 0-5 8.43 ± 0.61 284 ± 62 96 ± 10 
 5-10 8.19 ± 0.58 292 ± 59 98 ± 10 
Sodium phosphate 10-15 8.19 ± 0.61 293 ± 60 98 ± 10 
 15-20 7.95 ± 0.60 321 ± 64 99 ± 11 
 0-20 32.77 ± 2.31 297 ± 58 98 ± 10 
Note: rpm = revolutions per minute. 468 
Table 3. The effects of sodium phosphate supplementation on various physiological responses during 469 











 0-5 3.58 ± 0.61 144.4 ± 11.6 95.4 ± 20.5 0.91 ± 0.06 14.2 ± 1.3 
 5-10 3.67 ± 0.55 153.7 ± 12.0 103.0 ± 22.6 0.91 ± 0.05 15.6 ± 1.3 
Placebo 10-15 3.64 ± 0.56 155.8 ± 13.2 105.0 ± 24.7 0.90 ± 0.05 16.2 ± 1.5 
 15-20 3.79 ± 0.56 162.0 ± 13.0 117.0 ± 29.5 0.92 ± 0.06 17.9 ± 1.5 
 0-20 3.67 ± 0.55 154.1 ± 11.7 105.1 ± 22.7 0.91 ± 0.05 - 
 0-5 3.55 ± 0.72 144.7 ± 14.9 96.8 ± 22.3 0.93 ± 0.06 14.5 ± 1.2 
 5-10 3.67 ± 0.67 155.2 ± 14.0 105.6 ± 23.3 0.93 ± 0.05 15.9 ± 1.1 
Sodium phosphate 10-15 3.65 ± 0.62 158.9 ± 13.9 109.6 ± 24.5 0.92 ± 0.05 16.7 ± 1.3 
 15-20 3.79 ± 0.62 164.9 ± 13.1 123.8 ± 28.7 0.95 ± 0.06 18.3 ± 1.3 
 0-20 3.67 ± 0.64 156.0 ± 13.1 108.9 ± 22.9 0.93 ± 0.05 - 

















Figure 1. The effects of sodium phosphate supplementation on blood lactate concentration prior to and 482 
immediately following a 20 km cycling time-trial (N = 20). Values are means ± standard deviation. * 483 
indicates significantly different (p < 0.05) from placebo. 484 
